Is Pfizer (PFE) A Worthy Long-Term Investment?

Saturna Capital, an investment management firm, published its “Amana Funds” third-quarter 2021 investor letter – a copy of which can be downloaded here. For the third quarter of 2021, the Amana Income Fund Investor Shares returned -2.54% and the Institutional Shares returned -2.50%. The Amana Growth Fund Investor Shares returned 0.95%, ahead of the 0.58% return of the S&P 500 Index, as well as the NASDAQ Composite return of -0.22% for the same period. You can take a look at the fund’s top 5 holdings to have an idea about their best picks for 2021.

Saturna Capital Amana Funds, in its Q3 2021 investor letter, mentioned Pfizer Inc. (NYSE: PFE) and discussed its stance on the firm. Gartner, Inc. is a New York, New York-based pharmaceutical industry company with a $289.2 billion market capitalization. PFE delivered a 39.35% return since the beginning of the year, while its 12-month returns are up by 20.52%. The stock closed at $51.48 per share on December 06, 2021.

Here is what Saturna Capital Amana Funds has to say about Pfizer Inc. in its Q3 2021 investor letter:

“The Fund’s strongest performer during the quarter was pharmaceutical manufacturer Pfizer. The company submitted trial data to the FDA for use of its COVID-19 vaccine for younger children, and it is widely expected that the FDA will approve it. Health authorities also began recommending booster shots of the Pfizer vaccine for select populations, further increasing demand for vaccinations.”

Photo by Spencer Davis on Unsplash

Based on our calculations, Pfizer Inc. (NYSE: PFE) was not able to clinch a spot in our list of the 30 Most Popular Stocks Among Hedge Funds. PFE was in 74 hedge fund portfolios at the end of the third quarter of 2021, compared to 67 funds in the previous quarter. Pfizer Inc. (NYSE: PFE) delivered a  9.72% return in the past 3 months.

Disclosure: None. This article is originally published at Insider Monkey.